Dendritic cell vaccine - DanDrit Biotech

Alternative Names: MCV - DanDrit Biotech; MelCancerVac

Latest Information Update: 08 Mar 2017

Price : ^*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator DanDrit Biotech A/S
Class Cancer vaccines; Dendritic cell vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase II/III Colorectal cancer
No development reported Non-small cell lung cancer

Most Recent Events

01 Sep 2016 DanDrit Biotech has various patents pending for Dendritic cell vaccine (DanDrit Biotech 10-K, September 2016).
16 Jun 2015 No recent reports of development identified - Phase-II for Non-small cell lung cancer in Denmark (SC)
28 Apr 2015 DanDrit Biotech and the GISCAD Foundation plan for the phase III VIVA trial for Colorectal cancer (Adjuvant therapy, Prevention of relapse, late-stage disease, Metastatic disease) in Italy

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.